WithdrawnPhase 3

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

Stopped: Our local committee has denied the approval request

0Started 2020-10-15

Plain-language summary

At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness. There is hypothesis that in predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and by microvascular pulmonary thrombosis. The investigators suggest that thrombolytic therapy may be beneficial when compared to standard care in patients with SARS-CoV-2 and severe respiratory failure.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Severe pulmonary coronavirus disease 19 (COVID 19) with suspect for MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome)
✓. P/F ratio \<200 mmHg\> 70 mmHg
✓. a.) Contrast CT scan positive for pulmonary thrombosis, OR b.) Contrast CT scan negative for pulmonary thrombosis:

What they're measuring

P/F (PaO2/FiO2) change during the first 72hrs after the end of the procedure in adult patients with severe atypical ARDS caused by SARS-2-CoV.

Timeframe: Each 6 hours during first 3 days after the end of thrombolysis procedure.

Trial details

NCT IDNCT04453371

SponsorNegovsky Reanimatology Research Institute

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2021-01-15

View on ClinicalTrials.gov More Acute Respiratory Distress Syndrome trials